This content is intended for healthcare professionals in Egypt, Saudi Arabia, Jordan and Turkey.

Please confirm that you are a healthcare professional in one of those countries.

Decline

This activity has been sponsored by Janssen Pharmaceuticals. Janssen Pharmaceuticals provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Bladder Cancer View Time: 7 mins

touchFEATURE The role of fibroblast growth factor receptor (FGFR) alterations in advanced urothelial carcinoma

Watch to learn more about FGFR alterations and how a consensus on molecular classification impacts our understanding of muscle-invasive bladder cancer.1,2

 
Videos
The details matter in the treatment of advanced urothelial cancers

This short video summarises the role of molecular profiling in advanced urothelial carcinomas.1,2

1/3 Next Chapter
 
An introduction to the fibroblast growth factor receptor (FGFR)

This video infographic introduces the involvement of FGFR alterations in tumorigenesis, and their prevalence in various cancer types including urothelial carcinoma.3-6

2/3 Next Chapter
 
Could a molecular understanding of disease change our approach to advanced urothelial carcinoma?

Dr Ignacio Durán, Medical Oncologist at Hospital Universitario Marqués de Valdecilla, Spain, discusses a consensus molecular classification for muscle-invasive bladder cancer and how this may lead to more targeted approaches in the treatment of advanced urothelial carcinoma.2

3/3 Leave Feedback
Leave Feedback
Learning Objectives & Overview
Overview

Fibroblast growth factor receptor (FGFR) alterations are present in a wide variety of tumour types, including urothelial carcinoma.1-3 Alterations in the FGR/FGFR pathway can cause aberrant signalling that is implicated in multiple tumorigenic processes.4-6 A consensus molecular classification for muscle-invasive bladder cancer defines a subtype expressing a high percentage of FGFR alterations.2 This consensus may open the door to more targeted approaches in the treatment of advanced urothelial carcinoma.2

For more information, please visit FGFR alterations in oncology.

 

Learning Objectives

After watching this activity, participants should be better able to:

  • Understand the FGFR pathway and its potential involvement in urothelial carcinoma5
  • Recognise that FGFR alterations are common in certain types of urothelial carcinoma3
  • Discuss a consensus molecular classification for muscle-invasive bladder cancer and its potential impact on clinical practice2
References
References
  1. Inamura K. Bladder Cancer: New Insights into Its Molecular Pathology. Cancers. 2018;10(4):100.
  2. Kamoun A, de Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-33.
  3. Helsten T, Elkin S, Arthur E, et al. he FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016;22(1):259-267.
  4. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014; 34(2):280-300.
  5. Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171-187.
  6. Ahmad I, Iwata T, Leung HY, et al. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta. 2012;1823(4):850-860.
Downloads

View and download resources from this activity to support your learning and share with colleagues

Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72